LUNG

Pulmonx Corp

$1.45 -0.08 (-5.23%) At close · Jul 8

Market Cap

$61.88M

42,237,203

Equibles Rating blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Neutral Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 16.9 · calm Equity put/call 0.86

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg −12%

below

Price vs 50-day avg +4%

above

RSI (14) 53

neutral

MACD trend Positive

52-week position 12%

near low

Momentum

relative strength

Very Weak

1-month return −3%

trailing

6-month return −26%

trailing

YTD return −34%

this year

Relative strength −33%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $1 › 200d $2 — 200d above 50d

Institutional flow Distributing

1 of 112 funds reported for Jun 30 · net -740 sh shares

Insider flow Distributing

Net -$144.0K over 90 days · 100% sells

Short interest Falling

5.36% of float · ▼ -19.7% MoM · 7.2 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

112 holders — mid 3-yr range

Squeeze score 59

elevated · 0–100

Fundamentals

Strong

Revenue growth +8%

Y/Y

Gross margin 74%

expanding

EPS growth +8%

Y/Y

Free cash flow $-32.8M

Balance sheet $32.7M

net cash

Quant / Vol

risk profile

Very High

Volatility 99%

annualized · 1-yr

Max drawdown −69%

past year

ATR 8.2%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Up next

Next earnings call

Jul 28, 2026 Est · unconfirmed · in 3 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed May 4, 2026

AI Brief

TL;DR.

Bullish

Bearish

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Guidance & track record what management promised — and delivered

Latest guidance · from the 8-K filed Apr 29, 2026

Revenue · full year 2026 Maintained $90M – $92M

prior FY $90.5M midpoint +0.6% Y/Y

Gross margin · full year 2026 Maintained 75%

Total operating expenses · full year 2026 Initiated $113M – $115M

Cash, cash equivalents, and marketable securities decrease · full year 2026 Initiated $23M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral

2 · 2 · 2

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−12% Bearish

Price vs 50-day avg

+4% Bullish

RSI (14)

53 Neutral

MACD trend

Positive Bullish

52-week position

12% Bearish

Market signals — smart money & positioning

Bearish · 2 of 6

Trend (MA cross) No cross

50d $1 › 200d $2 — 200d above 50d

Institutional flow Distributing

1 of 112 funds reported for Jun 30 · net -740 sh shares

Insider flow Distributing

Net -$144.0K over 90 days · 100% sells

Short interest Falling

5.36% of float · ▼ -19.7% MoM · 7.2 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

112 holders — mid 3-yr range

Price context

position in its 52-week range

52-wk low $1 Now $1 · 12% 52-wk high $4

vs 200-day avg -12% vs 50-day avg +4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from its earnings releases, calls, and filings

Metric	Latest	Period	YoY
Adjusted EBITDA loss non-GAAP	-$8.5M	first quarter of 2026	—

adjusted EBITDA loss excluding restructuring charges non-GAAP	$7M	Q1 FY2026 call	—
new U.S. treating centers	15	Q1 FY2026 call	—
new U.S. treating centers added	15	Q1 2026 call	—
noncash stock-based compensation expense non-GAAP	$3.8M	Q1 2026 call	—
one-time restructuring costs in operating expenses non-GAAP	$1.4M	Q1 2026 call	—

Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

Versus peers

Medical Devices — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
LUNG Pulmonx Corp this stock	$61.88M	-34.4%	+8.0%	—	5.4%
ABT Abbott Laboratories	$164.43B	-23.6%	+5.7%	26.4	1.3%
SYK Stryker Corp	$125.40B	-6.8%	+11.2%	37.9	1.6%
MDT Medtronic plc	$105.46B	-13.9%	+8.4%	22.1	1.4%
BSX Boston Scientific Corp	$66.87B	-53.0%	+5.5%	18.8	2.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

112

% held: 74.0%
Reported: 1 of 112
Top holder: PRIMECAP MANAGEMENT CO/CA/

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Falling

Shares short

2.3M

Days to cover: 7.2d
Change: -554.2K sh

View

Short Volume

Short vol %

19%

As of: Jul 9, 2026

Short Total

View

Fails to Deliver

FTD shares

Value: $73
As of: Jun 10, 2026

View

Off-Exchange

Off-exchange %

62.7%

Week of: May 4, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$144.0K

Buyers / Sellers: 0 / 4

Buyers Sellers

View

Financials

Revenue (FY)

$90.5M

Net income (FY): $-54.0M
EPS diluted: $-1.33

View

Filings

SEC Filings

Latest

8-K

Filed: Jun 4, 2026
This year: 7

View

Proposed Sales

Value

$95.3K

Shares: 48.9K
Filed: Jan 22, 2026

View

Earnings & Events

Earnings Calls

Last call

May 12, 2026

View

Performance

	5D	20D	120D	MTD	YTD
LUNG	+11.5%	-2.7%	-25.6%	+11.5%	-34.4%
SPY	-0.2%	+0.8%	+7.4%	-0.2%	+9.3%
vs SPY	+11.7%	-3.5%	-33.1%	+11.7%	-43.7%

Key facts CIK 1127537 CUSIP 745848101 13F (30d) 1 filings 1 filers Visit website

LUNG

Price & Indicators

Technicals

Key metrics

Versus peers

At a glance

Performance